Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- COVID-19
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This is a randomized, double-blind, placebo-controlled, design. We propose the administration of an investigational drug in patients with high predicted short-term mortality secondary to COVID-19 disease. 30 Patients will be randomly assigned in a 1:1 ratio to two study arms that will receive clazakizumab at a dose of 25 mg or placebo.Masking: Triple (Participant, Care Provider, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 100 years
- Gender
- Both males and females
Description
In this study Investigators propose to administer clazakizumab to patients with severe COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients wi...
In this study Investigators propose to administer clazakizumab to patients with severe COVID-19 infection manifest by pulmonary failure and a clinical picture consistent with a cytokine storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in which 30 patients will be enrolled and randomly assigned in a 1:1 ratio to three study arms that will receive clazakizumab at a dose of 25 mg or placebo. The primary endpoint is patient safety assessed by serious adverse events associated with clazakizumab or placebo. The secondary endpoints are: incidence of intubation, time to extubation, length of ICU stay, severity of AKI, need for RRT, duration of RRT, trend in C-reactive protein, and patient survival at 28 and 60 days.
Tracking Information
- NCT #
- NCT04363502
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Nada Alachkar, MD Johns Hopkins University